Projects per year
Personal profile
Education
- 2012 PhD, Institute of Clinical Medicine, National Cheng Kung University
Experience
- 2005.7~Present Attending Physician, Department of Internal Medicine, NCKUH
- 2013.2~2015.8 Clinical Assistant professorr/Department of Internal Medicine, NCKU
- 2015.8~present Assistant Professor/Institute of Clinical Medicine, NCKU
Research Interests
- Clinical Oncology
- Anti-Cancer Pharmacology
- DNA Repair and Anti-Oxidant Stress in Oncology
- Cellular Resistance to Anti-Cancer Therapy and its Clinical Application
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Wen-Pin Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 15 Finished
-
-
以多重研究法解開組織缺氧-纖維化循環在胰臟癌之病理機制及發展新穎治療策略-開創抗Hypoxia之胰臟癌新治療—藉由pH-sensitive攜帶Sitravatinib的奈米粒子，以提升PD-1 抗體之療效( II )
21-08-01 → 22-07-31
Project: Research project
-
-
以多重研究法解開組織缺氧-纖維化循環在胰臟癌之病理機制及發展新穎治療策略-開創抗Hypoxia之胰臟癌新治療—藉由pH-sensitive攜帶Sitravatinib的奈米粒子，以提升PD-1 抗體之療效( I )
20-08-01 → 21-07-31
Project: Research project
-
PD-L1不只是Biomarker！探討肺癌細胞本身的PD-L1促進轉移的機轉，及其與TIP60-mediated 癌症EMT的相關性
19-08-01 → 20-07-31
Project: Research project
-
APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance
Wu, C. K., Shiu, J. L., Wu, C. L., Hung, C. F., Ho, Y. C., Chen, Y. T., Tung, S. Y., Yeh, C. F., Shen, C. H., Liaw, H. & Su, W. P., 2024 Jun 10, In: Nucleic acids research. 52, 10, p. 5676-5697 22 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
THOR cohort 2 investigators, 2024 Jan, In: Annals of Oncology. 35, 1, p. 107-117 11 p.Research output: Contribution to journal › Article › peer-review
32 Citations (Scopus) -
Polymeric nano-formulation of spectrum selective RTK inhibitor strengthens anti-cancer effects via immune remodeling by endoplasmic reticulum stress-modulating mitochondrial metabolism
Chang, L. C., Chin, Y. C., Wu, P. C., Wei, Y. F., Wu, H. C., Cheng, T. Y., Liu, Y. F., Huang, C. C. & Su, W. P., 2024 Feb, In: Nano Today. 54, 102070.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Prussian blue analog with separated active sites to catalyze water driven enhanced catalytic treatments
Wang, L. C., Chiou, P. Y., Hsu, Y. P., Lee, C. L., Hung, C. H., Wu, Y. H., Wang, W. J., Hsieh, G. L., Chen, Y. C., Chang, L. C., Su, W. P., Manoharan, D., Liao, M. C., Thangudu, S., Li, W. P., Su, C. H., Tian, H. K. & Yeh, C. S., 2023 Dec, In: Nature communications. 14, 1, 4709.Research output: Contribution to journal › Article › peer-review
Open Access19 Citations (Scopus) -
Atomically dispersed golds on degradable zero-valent copper nanocubes augment oxygen driven Fenton-like reaction for effective orthotopic tumor therapy
Wang, L. C., Chang, L. C., Chen, W. Q., Chien, Y. H., Chang, P. Y., Pao, C. W., Liu, Y. F., Sheu, H. S., Su, W. P., Yeh, C. H. & Yeh, C. S., 2022 Dec, In: Nature communications. 13, 1, 7772.Research output: Contribution to journal › Article › peer-review
Open Access20 Citations (Scopus)